Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Clinical Genitourinary Cancer|February 4, 2025
Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II TrialEarle F Burgess, Claud M Grigg, Danielle Boselli, et al.Clinical Genitourinary Cancer|May 2, 2024
Thrombosis Rates and Genetic Thrombophilia Risk Among Patients With Advanced Germ Cell Tumors Treated With ChemotherapyLandon C Brown, Myra Robinson, Michael McCormack, et al.Clinical Genitourinary Cancer|June 3, 2020
PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial CarcinomaLandon C Brown, Jason Zhu, Matthew K Labriola, et al.Prostate Cancer and Prostatic Diseases|March 16, 2022
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancerLandon C Brown, Susan Halabi, Jason A Somarelli, et al.JCO Precision Oncology|July 17, 2020
CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint BlockadeMichael T Schweizer, Gavin Ha, Roman Gulati, et al.Journal for Immunotherapy of Cancer|March 3, 2021
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer typesLandon C Brown, Matthew D Tucker, Ramy Sedhom, et al.Biomarker Research|November 4, 2021
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinomaMatthew D Tucker, Landon C Brown, Yu-Wei Chen, et al.Cancer Medicine|March 2, 2021
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomesAndrew L Laccetti, Benjamin Garmezy, Lianchun Xiao, et al.Cancers|August 12, 2022
The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell CarcinomaYu-Wei Chen, Matthew D Tucker, Landon C Brown, et al.Journal for Immunotherapy of Cancer|October 17, 2022
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinomaLandon C Brown, Jason Zhu, Kunal Desai, et al.Pageof 3